Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Zhi

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology|September 18, 2018
[KRAS mutations analysis in mucinous epithelial lesions of the endometrium]X Z Zheng, Y Zhan, J H Ma, et al.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Journal of Clinical Otorhinolaryngology Head and Neck Surgery|May 19, 2018
[The clinical value of China Savin pollen extract used for skin prick test]Kai Guan, J X Zhou, R Q Wang, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|January 8, 2024
[Risk factors of systemic allergic reactions caused by subcutaneous allergen immunotherapy]L S Li, K Guan, J Yin, et al.
Journal of Physics. Condensed Matter : an Institute of Physics Journal|July 13, 2016
μSR investigation of a new diluted magnetic semiconductor Li(Zn,Mn,Cu)As with Mn and Cu codoping at the same Zn sitesS L Guo, Y Zhao, H Y Man, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C Zhou, Y L Wu, G Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2013
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G Chen, J Feng, C Zhou, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology|September 18, 2018
[KRAS mutations analysis in mucinous epithelial lesions of the endometrium]X Z Zheng, Y Zhan, J H Ma, et al.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Journal of Clinical Otorhinolaryngology Head and Neck Surgery|May 19, 2018
[The clinical value of China Savin pollen extract used for skin prick test]Kai Guan, J X Zhou, R Q Wang, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|January 8, 2024
[Risk factors of systemic allergic reactions caused by subcutaneous allergen immunotherapy]L S Li, K Guan, J Yin, et al.
Journal of Physics. Condensed Matter : an Institute of Physics Journal|July 13, 2016
μSR investigation of a new diluted magnetic semiconductor Li(Zn,Mn,Cu)As with Mn and Cu codoping at the same Zn sitesS L Guo, Y Zhao, H Y Man, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C Zhou, Y L Wu, G Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2013
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G Chen, J Feng, C Zhou, et al.
Pageof 5